
Pharmacally
Narcolepsy
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Narcolepsy
Health TidingsFDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for NarcolepsyThe U.S. FDA has granted Fast Track designation to Lundbeck’s investigational oral orexin 2 receptor agonist Lu AH69593 for narcolepsy.Fact-Checked
New Drug ApprovalChina Approves Takeda’s ORZEYFUL for Narcolepsy Type 1China’s NMPA has approved Takeda’s ORZEYFUL (oveporexton) for adolescents aged 16 years and older and adults with narcolepsy type 1.Fact-Checked
Clinical TrialsAlixorexton Shows Sustained Wakefulness and Daytime Sleepiness Benefits for Up to Nine Months in NarcolepsyAlkermes has reported positive interim long-term extension data showing alixorexton maintained clinically meaningful improvements in wakefulness, excessive daytime sleepiness, cognition, and fatigue for up to nine months in…Fact-Checked
Clinical TrialsJazz Highlights New Xywav Data Showing Cardiometabolic Benefits and Personalized Dosing in Narcolepsy and Idiopathic HypersomniaLate-breaking SLEEP 2026 data highlight Xywav’s potential to improve cardiometabolic risk markers and support individualized dosing strategies across narcolepsy and idiopathic hypersomnia treatment settings.Fact-Checked
Clinical TrialsOveporexton Improves Daily Functioning and Sleep in Narcolepsy Type 1Phase 3 data presented at SLEEP 2026 show Takeda’s oveporexton significantly improved daily functioning, cognition, and sleep quality in narcolepsy type 1.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.